PARP14 and neoplasm: Furthermore, Wong et al. described that catalytic inhibition of PARP14 with the selective inhibitor RBN012759 restores sensitivity to PD-1 treatment, associated with a decrease in regulatory T cells, enabling sustained tumor regression and generating an antitumor immune memory following co-treatment with PARP14 inhibitor and anti-PD-1 therapy [82,83].